For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development - licenses acquired | - | 252 | ||
| Net revenue | 63,262 | 57,675 | ||
| Cost of goods - (excluding amortization of acquired intangible assets) | 20,924 | 20,879 | ||
| Asset impairment | - | 3,692 | ||
| Amortization of acquired intangible assets | 4,258 | 3,424 | ||
| Research and development | 11,901 | 56,629 | ||
| Loss recovery | - | 4,553 | ||
| Selling, general and administrative | 96,400 | 87,731 | ||
| Total operating expenses | 133,483 | 168,054 | ||
| Loss from operations | -70,221 | -110,379 | ||
| Interest income | 2,485 | 2,683 | ||
| Interest expense and financing fee | 10,106 | 13,527 | ||
| Loss on common stock warrant liabilities | -398 | -638 | ||
| Gain from deconsolidation of subsidiary | 27,127 | - | ||
| Other income | 17,578 | 1,318 | ||
| Total other income (expense) | 36,686 | -10,164 | ||
| Loss before income tax expense | -33,535 | -120,543 | ||
| Income tax expense (benefit) | -620 | 312 | ||
| Net loss | -32,915 | -120,855 | ||
| Attributable to non-controlling interests | -39,730 | -74,858 | ||
| Net income (loss) attributable to fortress | 6,815 | -45,997 | ||
| Preferred a dividends declared and paid and/or cumulated, and fortress' share of subsidiary deemed dividends | 8,697 | 9,893 | ||
| Net loss attributable to common stockholders | -1,882 | -55,890 | ||
| Basic EPS | -0.07 | -2.69 | ||
| Diluted EPS | -0.07 | -2.69 | ||
| Basic Average Shares | 27,901,889 | 20,784,334 | ||
| Diluted Average Shares | 27,901,889 | 20,784,334 | ||
Fortress Biotech, Inc. (FBIO)
Fortress Biotech, Inc. (FBIO)